Apparently, this particular trial was for tumor cells that express CD19:
http://www.uphs.upenn.edu/news/news_releases/2012/12/tcell/
I am wondering if they also filtered patients by blood type like in the T-cell trial for synovial sarcoma where you have to be HLA-A2 positive?
This is probably the trial?